Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
Returns on capital
Kalaris Therapeutics Inc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.1%
avg -18.8%
ROIC
-41.1%
avg 347.5%
ROA
-35.7%
avg -128.6%
Analysis
ROA is currently the strongest return metric at -35.7% versus its period average of -128.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Andrew Oxtoby | President, Chief Executive Officer & Director | USD 882.04K | 52 | 222.00K | 1.19% |
Matthew Feinsod | Chief Medical Officer | USD 665.37K | 55 | 135.00K | 0.72% |
Napoleone Ferrara | Independent Director & Co-Founder | USD 46.66K | 69 | 9.00K | 0.05% |
Michael Philip Dybbs | Director & Co-Founder | USD 39K | 51 | — | — |
Srinivas Akkaraju | Director & Co-Founder | USD 39K | 58 | 9.00K | 0.05% |
Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller | — | 37 | — | — |
Liisa Ann Bayko | Chief Financial Officer & Treasurer | — | 55 | 0 | <0.01% |
Jill E. Porter | Senior Vice President of CMC | — | — | — | — |
Kristine Curtiss | Senior Vice President of Clinical | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$6.18M
Sells
1
$12,868.80
Net Transaction Value
+$6.17M
Net buying
Most Active
AKKARAJU SRINIVAS
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 20, 26May 20, 2026 | AKKARAJU SRINIVAS Indirect | Buy | $1.2M$1,179,969.00 |
| Mar 20, 26Mar 20, 2026 | Hagen Brett R Direct | Sell | $12.9K$12,868.80 |
| Dec 18, 25Dec 18, 2025 | AKKARAJU SRINIVAS Indirect | Buy | $5M$5,000,005.74 |
Summary
Insiders reported 2 buys worth $6.18M and 1 sells worth $12,868.80 over the last 12 months. That adds up to net buying of $6.17M. AKKARAJU SRINIVAS was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Kalaris Therapeutics Inc compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about KLRS's management, answered from reported figures.
Who manages KLRS?
Kalaris Therapeutics Inc (KLRS) lists 9 active executives. The top listed executive is Michael Philip Dybbs, Director & Co-Founder.
Are KLRS insiders buying or selling?
Recent insider activity shows net buying of $32.15M.
Continue the stock analysis
Jump to another research area for this company.